News & Updates

H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
20 Nov 2022

Among patients with nonalcoholic fatty liver disease (NAFLD), eradication treatment against Helicobacter pylori may help improve liver steatosis and metabolic parameters, a recent study has found.

H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
20 Nov 2022
Low use of CVD prevention strategies in people with HIV
Low use of CVD prevention strategies in people with HIV
18 Nov 2022
COVID-19 vaccination poses no risk of herpes zoster infection
COVID-19 vaccination poses no risk of herpes zoster infection
18 Nov 2022

COVID-19 vaccines do not appear to carry any increased risk of developing herpes zoster infection among recipients, a study has reported.

COVID-19 vaccination poses no risk of herpes zoster infection
18 Nov 2022
Moderate dairy intake protects against COVID-19
Moderate dairy intake protects against COVID-19
17 Nov 2022
Joint replacement ERAS program reforms surgical care during pandemic
Joint replacement ERAS program reforms surgical care during pandemic
15 Nov 2022
COVID-19 infection affects faecal microbiota and this condition may persist long after recovery from the disease.
COVID-19 infection affects faecal microbiota and this condition may persist long after recovery from the disease.
15 Nov 2022 byPank Jit Sin

COVID-19 infection is associated with faecal microbiota dysbiosis*, especially those that cause more severe disease, says a prominent researcher. However, there is ambiguity as to whether it is a meaningful association or an epiphenomenon**. 

COVID-19 infection affects faecal microbiota and this condition may persist long after recovery from the disease.
15 Nov 2022
Dolutegravir: A better choice for HIV viral suppression in pregnancy?
Dolutegravir: A better choice for HIV viral suppression in pregnancy?
13 Nov 2022 byRoshini Claire Anthony

Among pregnant individuals on antiretroviral therapy (ART) for HIV-1 infection, those on dolutegravir had the greatest viral suppression rates at delivery, a recent US-based observational study showed. However, birth outcomes generally did not differ between dolutegravir recipients and those on various other ART regimens.

Dolutegravir: A better choice for HIV viral suppression in pregnancy?
13 Nov 2022